JP2024532486A5 - - Google Patents

Info

Publication number
JP2024532486A5
JP2024532486A5 JP2024513938A JP2024513938A JP2024532486A5 JP 2024532486 A5 JP2024532486 A5 JP 2024532486A5 JP 2024513938 A JP2024513938 A JP 2024513938A JP 2024513938 A JP2024513938 A JP 2024513938A JP 2024532486 A5 JP2024532486 A5 JP 2024532486A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence described
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/042429 external-priority patent/WO2023034555A1/en
Publication of JP2024532486A publication Critical patent/JP2024532486A/ja
Publication of JP2024532486A5 publication Critical patent/JP2024532486A5/ja
Pending legal-status Critical Current

Links

JP2024513938A 2021-09-02 2022-09-02 Dll3を標的とする抗原認識受容体及びその使用 Pending JP2024532486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240189P 2021-09-02 2021-09-02
US63/240,189 2021-09-02
PCT/US2022/042429 WO2023034555A1 (en) 2021-09-02 2022-09-02 Antigen recognizing receptors targeting dll3 and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532486A JP2024532486A (ja) 2024-09-05
JP2024532486A5 true JP2024532486A5 (cg-RX-API-DMAC10.html) 2025-09-10

Family

ID=85411573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513938A Pending JP2024532486A (ja) 2021-09-02 2022-09-02 Dll3を標的とする抗原認識受容体及びその使用

Country Status (7)

Country Link
US (1) US20240252640A1 (cg-RX-API-DMAC10.html)
EP (1) EP4396214A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024532486A (cg-RX-API-DMAC10.html)
CN (1) CN118215675A (cg-RX-API-DMAC10.html)
AU (1) AU2022339815A1 (cg-RX-API-DMAC10.html)
CA (1) CA3230627A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023034555A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
CR20200539A (es) * 2018-04-10 2021-07-01 Kite Pharma Inc Receptores quiméricos de dll3 y métodos para su uso
MX2021010441A (es) * 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
MX2021012336A (es) * 2019-04-08 2021-11-12 Phanes Therapeutics Inc Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos.
US12441789B2 (en) * 2019-07-11 2025-10-14 Memorial Sloan Kettering Cancer Center DLL3-targeting antibodies and uses thereof
EP4527466A3 (en) * 2019-07-17 2025-06-18 Legend Biotech Ireland Limited Anti-dll3 chimeric antigen receptors and uses thereof
IL327298A (en) * 2020-02-05 2026-05-01 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors with CD28 mutations and their use

Similar Documents

Publication Publication Date Title
JP2024500847A5 (cg-RX-API-DMAC10.html)
US11292841B2 (en) Anti-PD-1 nano-antibody and application thereof
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP6426713B2 (ja) Gpc3キメラ抗原受容体蛋白質をコードする核酸及びgpc3キメラ抗原受容体蛋白質を発現するtリンパ球
JP2021512635A5 (cg-RX-API-DMAC10.html)
US9200078B2 (en) Antibodies against prostate-specific stem cell antigen and use thereof
CN113784986B (zh) 间皮素特异性嵌合抗原受体及表达它的t细胞
CN109942712A (zh) 抗pd-l1/vegf双功能抗体及其用途
JP2020516276A5 (cg-RX-API-DMAC10.html)
JP2024023228A5 (cg-RX-API-DMAC10.html)
KR20180034430A (ko) Egfrviii 및 cd3에 결합하는 이중특이적 항체 작제물
KR20200092301A (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
JP2022513372A5 (cg-RX-API-DMAC10.html)
JP2023512452A (ja) Bcma指向性細胞免疫療法組成物および方法
KR20210021593A (ko) 다양한 구조 최적화를 갖는 t 세포-항원 커플러
JP2024509910A5 (cg-RX-API-DMAC10.html)
JP2025131589A (ja) 固形腫瘍を治療するための遺伝子操作しているγδ-T細胞及び遺伝子操作していないγδ-T細胞に関する組成物及び方法
JP2022548112A5 (cg-RX-API-DMAC10.html)
AU2023390820A1 (en) Chimeric antigen receptor
JP2023524995A5 (cg-RX-API-DMAC10.html)
CN114075287B (zh) 人源化bcma抗体和bcma-car-t细胞
KR102393776B1 (ko) Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
JP2024535740A5 (cg-RX-API-DMAC10.html)
KR20230072536A (ko) 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
WO2024193669A1 (zh) 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用